Iridium Reiterates FY24 Service Revenue Growth Outlook - Update
RTTNews
|
vor 33 Tagen
(RTTNews) - While reporting financial results for the first quarter on Thursday, Iridium Communications Inc. (IRDM) reiterated its total service revenue growth guidance for the full-year 2024.
For fiscal 2024, the company still projects service revenue growth of 4 to 6 percent, compared to the $584.5 million reported in 2023.
On average, seven analysts polled by Thomson Reuters expect the company to report revenues of $799.30 million for the year.
The Board of Directors plans to increase the quarterly dividend by 5.8 percent to $0.14 per share starting with the second quarter 2024 dividend.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
read more
Iridium Inks 5-Year Contract With L3Harris For Iridium Satellite Time And Location Service
Iridium Communications Inc. (IRDM) announced Tuesday a new five-year commercial contract with L3Harris Technologies (LHX) for the Iridium Satellite Time and Location (STL) service.
RTTNews
|
vor 42 Tagen
Iridium Boosts FY22 Service Revenue Growth Outlook - Update
While reporting financial results for the third quarter on Thursday, Iridium Communications Inc. (IRDM) raised its total service revenue growth guidance for the full-year 2022, based upon the momentum seen across all commercial business lines.
RTTNews
|
vor 579 Tagen
Iridium Boosts FY22 Revenue Outlook - Update
While reporting financial results for the second quarter on Tuesday, Iridium Communications Inc. (IRDM) raised its total service revenue growth guidance for the full-year 2022, based upon the momentum still seen from its extensive global ecosystem of business partners.
RTTNews
|
vor 665 Tagen
Citius Pharma Announce Positive Topline Results For Pivotal Phase 3 Clinical Trial Of Mino-Lok
Biopharmaceutical company Citius Pharmaceuticals, Inc. (CTXR) announced Tuesday positive topline results of its pivotal Phase 3 clinical trial of Mino-Lok, a novel antibiotic lock solution designed to salvage catheters in patients with central line-associated infections (CLABSI) or catheter-related bloodstream infections (CRBSI).
RTTNews
|
vor 4Std 9 Minuten
Lam Research Board Approves $10 Bln Share Buyback Authorization And 10-for-1 Stock Split
Lam Research Corp. (LRCX) announced Tuesday that its Board of Directors approved a $10 billion share repurchase authorization and a forward split of its outstanding shares of common stock at a ratio of 10:1.
RTTNews
|
vor 4Std 32 Minuten
Sensex, Nifty End Narrowly Mixed After Choppy Session
Indian shares ended modestly lower on Tuesday after U.S. Federal Reserve officials tempered investor enthusiasm about potential interest-rate cuts
RTTNews
|
vor 5Std 29 Minuten
European Shares Decline On US Rate Concerns
European stocks edged lower on Tuesday following cautious comments from Federal Reserve officials on inflation and the interest rate outlook.
RTTNews
|
vor 6Std 23 Minuten
Sanofi, OpenAI To Build AI Software To Boost Drug Development
French drug major Sanofi is teaming with artificial intelligence or AI startup OpenAI, the developer of highly popular generative AI chatbot ChatGPT, as well as Formation Bio, an AI and tech-driven drug developer, to build AI-powered software to accelerate drug development and bring new medicines more efficiently.
RTTNews
|
vor 6Std 29 Minuten